QuidelOrtho Corp (QDEL)

↓ Download CSV

CIK 0001906324 · Nasdaq · In Vitro & In Vivo Diagnostic Substances

  • Sector Manufacturing
  • Fiscal year ends Jan 1

In fiscal 2025, QuidelOrtho Corp reported revenue of $2.73B, down 1.9% from the prior year. The company ran a net loss, with a net margin of -41.5%. It held $5.77B in total assets against $3.85B in total liabilities.

Key ratios (FY2025)

-33.7%
Operating margin
-41.5%
Net margin
-58.9%
Return on equity
-1.9%
Revenue growth (YoY)
Metric (FY)202520242023202220212019
Revenue$2.73B$2.78B$3.00B$1.70B$1.66B
Operating Income-$919.20M-$1.96B$139.10M$906.00M$1.06B
Net Income-$1.13B-$2.05B-$10.10M$704.20M$810.30M
EPS (Diluted)$-16.69$-30.54$-0.15$16.43$18.60
Total Assets$5.77B$6.42B$8.56B$2.43B
Total Liabilities$3.85B$3.44B$3.56B$501.00M
Shareholders' Equity$1.92B$2.98B$5.01B$1.93B$1.33B$559.90M
Cash & Equivalents$169.80M$98.30M$118.90M$802.80M
Operating Cash Flow$105.20M$83.00M$280.20M$805.90M$629.70M
Capital Expenditures$188.20M$195.10M$209.30M$292.80M$64.90M
Shares Outstanding67.80M67.20M66.80M42.90M43.60M